BYE-LAWS FOR THE DEGREE OF MASTER OF SCIENCE IN PHARMACOLOGY OR CLINICAL PHARMACOLOGY UNDER THE AUSPICES OF THE

DEGREE OF MASTER OF SCIENCE IN PHARMACOLOGY

OR CLINICAL PHARMACOLOGY UNDER THE AUSPICES

OF THE FACULTY OF MEDICINE AND SURGERY

SUBSIDIARY LEGISLATION 327.340

BYE-LAWS FOR THE DEGREE OF MASTER OF

SCIENCE IN PHARMACOLOGY OR CLINICAL

PHARMACOLOGY UNDER THE AUSPICES OF THE

FACULTY OF MEDICINE AND SURGERY

2nd December, 2008

LEGAL NOTICE 322 of 2008, as amended by Legal Notices 487 of 2012

and 123 of 2014.

(1) The title of these bye-laws is the Bye-Laws for the

Degree of Master of Science in Pharmacology or Clinical

Pharmacology under the auspices of the Faculty of Medicine and

Surgery.

(2)

In these bye-laws, unless the context otherwise requires -

"the Board" means the Board of the Faculty of Medicine and

Surgery;

"the course" means the programme of study leading to the degree

of Master of Science in Pharmacology or Clinical Pharmacology;

"the Degree" means the degree of Master of Science in

Pharmacology or Clinical Pharmacology; and

"the Principal Regulations" means the General Regulations for

University Postgraduate Awards.

These bye-laws shall be applicable from 24th January 2014

onwards.

(1) The course shall be offered mainly by research in any

area of Pharmacology or Clinical Pharmacology.

(2) Subject to the availability of resources, the Board may

recommend to Senate the number of students to be admitted to the

Course and the areas of study in which it can offer expert guidance

and supervision. The areas offered and the maximum number of

students to be admitted shall be announced at the time of the call

for applications for admission to the course.

(3) If there are more eligible applicants than the number of

places available, applicants shall be selected after an interview by a

board appointed for the purpose. The board shall select applicants

using the following criteria

(a) the class of the degree;

(b) experience in the area of the proposed study;

(c) the research proposal; and

(d) their performance during an interview.

DEGREE OF MASTER OF SCIENCE IN PHARMACOLOGY

OR CLINICAL PHARMACOLOGY UNDER THE AUSPICES

OF THE FACULTY OF MEDICINE AND SURGERY

(1)

The course shall be open to applicants in possession of

(a) the degree of Doctor of Medicine and Surgery or the

degree of Bachelor of Dental Surgery; or

(b) the degree of Master of Dental Surgery awarded from

July 2018 onwards; or

(c) a Bachelor degree in Pharmacy or in a Health or Life

Science related area of study as deemed suitable by the

Board, with at least Second Class Honours; ore

(d) the degree of Bachelor of Science (Honours)

(Pharmaceutical science) with a classification of

second Class Honours or better.

(2) The admission of applicants under paragraph (c) of this

bye-law with Third Class Honours, who have obtained other

qualifications, including relevant experience following the first

cycle degree, may be made conditional on the results of an

assessment as the Board may deem appropriate.

The course shall extend over three semesters of full-time

study or the equivalent in part-time study.

The programme of study shall comprise study-units to

which a total of 90 credits are assigned, of which 30 credits are

assigned to taught study-units and 60 credits are assigned to a

dissertation study-unit.

The programme of study shall be published after approval

by Senate, normally not less than eight months prior to the

commencement of the course.

(1) The assessment of each taught study-unit shall be

completed by the end of the semester in which the teaching of the

study-unit is held.

(2) Students who fail in the assessment of not more than 10

credits for taught study-units shall be given the opportunity to re-

sit the failed assessments during the September supplementary

examination session.

(3) Students who fail in more than 10 credits or students who

after reassessment fail to obtain the credits for any study-unit, shall

be deemed to have failed the course.

(1) Students shall be required to submit an individual

dissertation of approximately 40,000 words in accordance with the

guidelines issued by the Board.

(2) Work on the dissertation may be undertaken throughout the

course after approval of the proposal. Each student shall be

assigned a supervisor who shall provide guidance and advice on a

regular basis during the period of study.

(1) Students shall be required to have regular contact with

their supervisor.

(2)

Supervisors shall submit to the Board progress reports for

DEGREE OF MASTER OF SCIENCE IN PHARMACOLOGY

OR CLINICAL PHARMACOLOGY UNDER THE AUSPICES

OF THE FACULTY OF MEDICINE AND SURGERY

each student under their supervision at the end of each semester of

studies, whether the student is following the course on a full-time

or a part-time basis. Such reports may include a recommendation to

either (a) extend the period of study in order to enable the student

to complete the dissertation; or (b) terminate studies prematurely if

the supervisor deems this to be proper in the circumstances,

provided that

(i)

the extension of the study period referred to in

(a) shall be in accordance with the provisions of

the Principal Regulations; and

(ii) the Board may not terminate studies prematurely

according to (b) until it has first given the

student a chance to be heard.

The Final Weighted Average Mark for the purpose of the

classification of the Degree shall be based on the results obtained

in all components of the programme of study, all credits being

weighted equally.

The provisions of the foregoing bye-laws shall apply

mutatis mutandis to courses followed on a part-time basis, and

subject to such changes as may reasonably be deemed by the Board

as necessary due to the part-time nature of the course.